| Rapamycin analogs as mTOR inhibitors |
2022-11-10 |
2022-12-15 |
|
| Ras inhibitors |
2022-10-07 |
2023-4-13 |
|
| Bicyclic compounds as allosteric shp2 inhibitors |
2022-9-13 |
2022-11-01 |
|
| Compounds that participate in cooperative binding and uses thereof |
2022-8-05 |
2022-9-01 |
|
| Shp2 inhibitor dosing and methods of treating cancer |
2022-7-03 |
2022-9-01 |
|
| Covalent ras inhibitors and uses thereof |
2022-5-26 |
2023-3-30 |
|
| Methods for inhibiting ras |
2022-5-25 |
2022-12-01 |
|
| Use of sos1 inhibitors with mtor inhibitors to treat cancers |
2022-5-11 |
2022-11-17 |
|
| Ras inhibitors |
2022-5-09 |
2022-7-29 |
|
| Ras inhibitors |
2022-5-09 |
2022-7-29 |
|
| Ras inhibitors |
2022-5-09 |
2022-7-29 |
|
| Bicyclic Heteroaryl Compounds and Uses of These |
2022-5-06 |
2022-7-29 |
|
| Covalent ras inhibitors and uses thereof |
2022-5-05 |
2022-11-10 |
|
| Ras inhibitors |
2022-5-05 |
2022-12-15 |
|
| Ras inhibitors |
2022-5-05 |
2023-4-06 |
|
| C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors |
2022-4-29 |
2023-2-23 |
|
| Use of sos1 inhibitors with ras inhibitors to treat cancers |
2022-4-08 |
2022-10-13 |
|
| Synthesis of rapamycin analog compounds |
2022-4-07 |
2022-12-22 |
|
| Methods for inhibiting ras |
2022-4-01 |
2022-10-06 |
|
| Process for preparing shp2 inhibitors |
2021-12-17 |
2022-6-23 |
|
| Sos1 inhibitors and uses thereof |
2021-12-16 |
2022-7-07 |
|
| Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3 … |
2021-12-01 |
2022-2-01 |
|
| 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl … |
2021-11-30 |
2021-12-23 |
|
| Ras inhibitors |
2021-9-15 |
2022-7-16 |
|
| Indole derivatives as ras inhibitors in the treatment of cancer |
2021-9-15 |
2023-4-13 |
|
| RAS INHIBITORS |
2021-9-15 |
2022-12-14 |
|
| Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
2021-9-03 |
2023-4-06 |
|
| Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
2021-9-03 |
2023-4-13 |
|
| Bicyclic heteroaryl compounds and uses thereof |
2021-8-24 |
2021-10-31 |
|
| Bicyclic heterocyclyl compounds and uses thereof |
2021-8-24 |
2021-10-31 |
|
| Compounds that participate in cooperative binding and uses thereof |
2021-6-20 |
2021-8-31 |
|
| Methods for delaying, preventing, and treating acquired resistance to ras … |
2021-6-16 |
2022-4-16 |
|
| Compounds that participate in cooperative binding and uses thereof |
2021-6-11 |
2022-5-12 |
|
| Compounds that participate in cooperative binding and uses thereof |
2021-6-10 |
2022-5-12 |
|
| Shp2 inhibitor compositions for use in treating cancer |
2021-4-06 |
2022-2-03 |
|
| Methods and reagents for analyzing protein-protein interfaces |
2021-1-28 |
2021-12-30 |
|
| Identifying new therapeutic agents |
2020-12-21 |
2022-3-17 |
|
| BICYCLIC HETEROARYL COMPOUNDS AND USES OF THESE |
2020-11-05 |
2022-2-09 |
|
| RAS INHIBITORS |
2020-11-04 |
2023-2-07 |
|
| RAS INHIBITORS |
2020-11-04 |
2022-2-09 |
|
| RAS INHIBITORS |
2020-11-04 |
2022-2-09 |
|
| RAS INHIBITORS |
2020-11-04 |
2022-4-27 |
|
| C26-linked rapamycin analogs as mtor inhibitors |
2020-10-30 |
2022-10-27 |
|
| Compositions of shp2 inhibitors, methods for treating cancer, and methods for … |
2020-10-09 |
2020-10-30 |
|
| Polycyclic compounds as allosteric shp2 inhibitors |
2020-6-11 |
2020-12-31 |
|
| Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
2020-4-10 |
2020-10-29 |
|
| Compositions comprising a shp2 inhibitor and methods for treating cancer |
2020-3-09 |
2020-6-19 |
|
| BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USES |
2020-3-02 |
2021-9-22 |
|
| BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USES |
2020-3-02 |
2021-9-22 |
|
| Derivatives of amphotericin B |
2020-2-25 |
2021-1-05 |
2021-1-05 |
| MACROCYCLIC COMPOUNDS AS COVALENT DRUGS LINKED TO RAS PROTEIN AND THEIR USE FOR … |
2019-12-20 |
2021-2-10 |
|
| COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF |
2019-12-20 |
2021-10-19 |
|
| Methods and reagents for analyzing protein-protein interfaces |
2019-10-03 |
2019-11-28 |
|
| Pyridine compounds as allosteric shp2 inhibitors |
2019-7-22 |
2020-1-16 |
|
| RAPAMYCIN ANALOGUES LINKED TO C40, C28 AND C-32 AS INHIBITORS OF MTOR |
2019-4-29 |
2020-10-21 |
|
| POLYCYCLIC COMPOUNDS AS ALLOSTERIC INHIBITORS OF SHP2 |
2018-12-14 |
2020-7-01 |
|
| PYRIDINE, PIRAZINE, AND TRIAZINE COMPOUNDS AS SHP2 ALLOSTERIC INHIBITORS |
2018-10-11 |
2020-6-10 |
|
| Shp2 inhibitor compositions and cancer treatment methods |
2018-9-06 |
2021-6-30 |
|
| 3-METHYLPIRAZINS 2,5-DISUSTITUTED AND 3-METHYLPIRAZINS 2,5,6-TRISUSTITUTED AS … |
2017-7-11 |
2018-10-17 |
|
| 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl … |
2017-7-11 |
2022-7-29 |
|
| Inhibiteurs de ras |
2022-10-07 |
2023-4-13 |
|
| Dérivés d'indole servant d'inhibiteurs dans le traitement du cancer |
2021-9-15 |
2023-4-13 |
|
| Compostos que participam de ligação cooperativa e usos dos mesmos |
2019-12-20 |
2021-10-19 |
|